<span item_type="fundamental" item_id="8e7ffa7c83c520c1c4afab6cae2f8c76" counter_id="ST/US/ENZB" env="prod"></span><span item_type="announcement" item_id="528077042920850177" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 6.402 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.05.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.374 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: Enzo Biochem, Inc. reported revenues of $6.4 million for the three months ended April 30, 2025, a decrease from $8.0 million in the same period in 2024, representing a 20% decline. For the nine months ended April 30, 2025, revenues were $19.9 million, down from $24.4 million in 2024, an 18% decrease.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Loss</strong>: The operating loss for the three months ended April 30, 2025, was $3.4 million, compared to $2.0 million in the same period in 2024. For the nine months ended April 30, 2025, the operating loss was $8.6 million, compared to $9.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li><li><strong>Net Loss</strong>: The net loss for the three months ended April 30, 2025, was $2.8 million, compared to $3.0 million in the same period in 2024. For the nine months ended April 30, 2025, the net loss was $7.7 million, compared to $12.7 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the nine months ended April 30, 2025, net cash used in operating activities was $14.2 million, compared to $25.2 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: For the nine months ended April 30, 2025, net cash provided by investing activities was $4.1 million, primarily due to the release of escrowed cash from the Labcorp Asset Purchase Agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Foreign Exchange Gain</strong>: A foreign exchange gain of $0.5 million was recognized in the three months ended April 30, 2025, compared to a loss of $0.5 million in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Strategic Review</strong>: On April 22, 2025, Enzo Biochem, Inc. announced that its Board of Directors had commenced a review of strategic alternatives, including a potential strategic transaction, business combination, full sale of the company, or return of excess capital to shareholders. The company has engaged BroadOak Capital Partners as a financial advisor for this process.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/316253/000121390025054828/ea0245769-10q_enzobio.htm"></span></li></ul>

Enzo Biochem, Inc. | 10-Q: FY2025 Q3 Revenue: USD 6.402 M